1
|
Md Idris MH, Mohd Amin SN, Mohd Amin SN, Nyokat N, Khong HY, Selvaraj M, Zakaria ZA, Shaameri Z, Hamzah AS, Teh LK, Salleh MZ. Flavonoids as dual inhibitors of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX): molecular docking and in vitro studies. Beni-Suef Univ J Basic Appl Sci 2022. [DOI: 10.1186/s43088-022-00296-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
Abstract
Background
Inflammation is known to involve in many pathological processes of different diseases, but the current therapy causes adverse effects. Thus, there is a great interest for the discovery of flavonoids as a valuable alternative to classical analgesic and anti-inflammatory agent with dual-inhibitory action, especially on both COX-2 and 5-LOX which can minimize or overcome this problem.
Results
In the present work, drug-likeness properties of the synthesized flavonoids via Lipinski’s Rule of Five were predicted using QikProp prior to evaluation of their COX and LOX inhibitory activities using enzyme assays. Subsequently, molecular docking was performed using GLIDE to analyse their binding behaviour. The results showed that all compounds obeyed the Lipinski’s Rule of Five. NPC6 and NPC7 had displayed better selectivity towards COX-2 as compared to Indomethacin with less than 50% inhibition against COX-1. In addition, these compounds also inhibited activity of 5-LOX. Their selectivity to COX-2 was due to the binding to hydrophobic region and extends to lobby region near the entrance of COX binding site forming hydrogen bond with Ser530. Interestingly, these compounds showed a similar binding mode as Zileuton in the active site of 5-LOX and formed hydrogen bond interaction with Ala424.
Conclusion
NPC6 and NPC7 had potential as dual inhibitor of COX-2 and 5-LOX. The scaffolds of these chemical entities are useful to be as lead compounds for the dual inhibition of COX-2 and 5-LOX.
Collapse
|
2
|
Md Idris MH, Mohd Amin SN, Mohd Amin SN, Wibowo A, Zakaria ZA, Shaameri Z, Hamzah AS, Selvaraj M, Teh LK, Salleh MZ. Discovery of polymethoxyflavones as potential cyclooxygenase-2 (COX-2), 5-lipoxygenase (5-LOX) and phosphodiesterase 4B (PDE4B) inhibitors. J Recept Signal Transduct Res 2021; 42:325-337. [PMID: 34323638 DOI: 10.1080/10799893.2021.1951756] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely prescribed to treat inflammatory-related diseases, pain and fever. However, the prolong use of traditional NSAIDs leads to undesirable side effects such as gastric, ulceration, and renal toxicity due to lack of selectivity toward respective targets for COX-2, 5-LOX, and PDE4B. Thus, targeting multiple sites can reduce these adverse effects of the drugs and increase its potency. A series of methoxyflavones (F1-F5) were synthesized and investigated for their anti-inflammatory properties through molecular docking and inhibition assays. Among these flavones, only F2 exhibited selectivity toward COX-2 (Selectivity Index, SI: 3.90, COX-2 inhibition: 98.96 ± 1.47%) in comparison with celecoxib (SI: 7.54, COX-2 inhibition: 98.20 ± 2.55%). For PDEs, F3 possessed better selectivity to PDE4B (SI: 4.67) than rolipram (SI: 0.78). F5 had the best 5-LOX inhibitory activity among the flavones (33.65 ± 4.74%) but less than zileuton (90.81 ± 0.19%). Docking analysis indicated that the position of methoxy group and the substitution of halogen play role in determining the bioactivities of flavones. Interestingly, F1-F5 displayed favorable pharmacokinetic profiles and acceptable range of toxicity (IC50>70 µM) in cell lines with the exception for F1 (IC50: 16.02 ± 1.165 µM). This study generated valuable insight in designing new anti-inflammatory drug based on flavone scaffold. The newly synthesized flavones can be further developed as future therapeutic agents against inflammation.
Collapse
Affiliation(s)
- Muhd Hanis Md Idris
- Integrative Pharmacogenomics Institute (iPROMISE), Universiti Teknologi MARA (UiTM) Selangor Branch, Puncak Alam Campus, Selangor, Malaysia
| | - Siti Norhidayah Mohd Amin
- Integrative Pharmacogenomics Institute (iPROMISE), Universiti Teknologi MARA (UiTM) Selangor Branch, Puncak Alam Campus, Selangor, Malaysia
| | - Siti Norhidayu Mohd Amin
- Integrative Pharmacogenomics Institute (iPROMISE), Universiti Teknologi MARA (UiTM) Selangor Branch, Puncak Alam Campus, Selangor, Malaysia
| | - Agustono Wibowo
- Faculty of Applied Science, Universiti Teknologi MARA (UiTM) Pahang Branch, Jengka Campus, Pahang, Malaysia
| | - Zainul Amiruddin Zakaria
- Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia (UPM), Serdang, Malaysia
| | - Zurina Shaameri
- Organic Synthesis Laboratory, Institute of Science (IOS), Universiti Teknologi MARA (UiTM) Selangor Branch, Puncak Alam Campus, Selangor, Malaysia
| | - Ahmad Sazali Hamzah
- Organic Synthesis Laboratory, Institute of Science (IOS), Universiti Teknologi MARA (UiTM) Selangor Branch, Puncak Alam Campus, Selangor, Malaysia
| | - Manikandan Selvaraj
- School of Engineering, Monash University (Malaysia Campus), Bandar Sunway, Malaysia
| | - Lay Kek Teh
- Integrative Pharmacogenomics Institute (iPROMISE), Universiti Teknologi MARA (UiTM) Selangor Branch, Puncak Alam Campus, Selangor, Malaysia
| | - Mohd Zaki Salleh
- Integrative Pharmacogenomics Institute (iPROMISE), Universiti Teknologi MARA (UiTM) Selangor Branch, Puncak Alam Campus, Selangor, Malaysia
| |
Collapse
|
3
|
Mohd Amin SN, Md Idris MH, Selvaraj M, Mohd Amin SN, Jamari H, Kek TL, Salleh MZ. Virtual screening, ADME study, and molecular dynamic simulation of chalcone and flavone derivatives as 5-Lipoxygenase (5-LO) inhibitor. Molecular Simulation 2020. [DOI: 10.1080/08927022.2020.1732961] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Affiliation(s)
- Siti Norhidayah Mohd Amin
- Integrative Pharmacogenomics Institute (iPROMISE), Universiti Teknologi MARA (UiTM) Selangor, Bandar Puncak Alam, Malaysia
- Faculty of Pharmacy, Universiti Teknologi MARA (UiTM) Selangor, Bandar Puncak Alam, Malaysia
| | - Muhd Hanis Md Idris
- Integrative Pharmacogenomics Institute (iPROMISE), Universiti Teknologi MARA (UiTM) Selangor, Bandar Puncak Alam, Malaysia
- Faculty of Pharmacy, Universiti Teknologi MARA (UiTM) Selangor, Bandar Puncak Alam, Malaysia
| | | | - Siti Norhidayu Mohd Amin
- Integrative Pharmacogenomics Institute (iPROMISE), Universiti Teknologi MARA (UiTM) Selangor, Bandar Puncak Alam, Malaysia
- Faculty of Pharmacy, Universiti Teknologi MARA (UiTM) Selangor, Bandar Puncak Alam, Malaysia
| | - Hisyam Jamari
- Integrative Pharmacogenomics Institute (iPROMISE), Universiti Teknologi MARA (UiTM) Selangor, Bandar Puncak Alam, Malaysia
| | - Teh Lay Kek
- Integrative Pharmacogenomics Institute (iPROMISE), Universiti Teknologi MARA (UiTM) Selangor, Bandar Puncak Alam, Malaysia
- Faculty of Pharmacy, Universiti Teknologi MARA (UiTM) Selangor, Bandar Puncak Alam, Malaysia
| | - Mohd Zaki Salleh
- Integrative Pharmacogenomics Institute (iPROMISE), Universiti Teknologi MARA (UiTM) Selangor, Bandar Puncak Alam, Malaysia
- Faculty of Pharmacy, Universiti Teknologi MARA (UiTM) Selangor, Bandar Puncak Alam, Malaysia
| |
Collapse
|